Viridian Therapeutics Stock Analysis

Viridian Stock Analysis Notes

About 100.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 3.03. Viridian Therapeutics last dividend was issued on the 13th of November 2020. The entity had 1:15 split on the 13th of November 2020. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts. Viridian Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 50 people. For more information please call Jonathan MBA at 617 272 4600 or visit https://www.viridiantherapeutics.com.

Viridian Therapeutics Investment Alerts

Viridian Therapeutics Upcoming and Recent Events

Viridian Largest EPS Surprises

View All Earnings Estimates

Viridian Therapeutics Environmental, Social, and Governance (ESG) Scores

Viridian Stock Institutional Investors

Note, although Viridian Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Viridian Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.08 B.

Viridian Profitablity

Management Efficiency

Viridian Therapeutics has return on total asset (ROA) of (0.3008) % which means that it has lost $0.3008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4989) %, meaning that it created substantial loss on money invested by shareholders. Viridian Therapeutics' management efficiency ratios could be used to measure how well Viridian Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 14th of December 2025, Return On Tangible Assets is likely to drop to -0.38. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Viridian Therapeutics' Total Assets are very stable compared to the past year. As of the 14th of December 2025, Non Currrent Assets Other is likely to grow to about 992.8 K, while Non Current Assets Total are likely to drop about 2.7 M.

Technical Drivers

As of the 14th of December 2025, Viridian Therapeutics has the Risk Adjusted Performance of 0.1783, semi deviation of 2.09, and Coefficient Of Variation of 410.81. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Viridian Therapeutics, as well as the relationship between them.

Viridian Therapeutics Price Movement Analysis

Viridian Therapeutics Insider Trading Activities

Viridian Therapeutics Predictive Daily Indicators

Viridian Therapeutics Corporate Filings

Viridian Therapeutics Forecast Models

Viridian Therapeutics' time-series forecasting models are one of many Viridian Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Viridian Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Viridian Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Viridian shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Viridian Therapeutics. By using and applying Viridian Stock analysis, traders can create a robust methodology for identifying Viridian entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Viridian analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Viridian analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Viridian Therapeutics stock analysis indicators help investors evaluate how Viridian Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Viridian Therapeutics shares will generate the highest return on investment. By understating and applying Viridian Therapeutics stock analysis, traders can identify Viridian Therapeutics position entry and exit signals to maximize returns.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in consumer price index. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.